CareDx's $19.3 Million Quarterly Profit Leans On An $8.6 Million Tax Benefit From The Naveris Deal
A $9.8 million valuation allowance release lifted third-quarter net income, while operations earned $8.1 million.
CareDx, which sells blood tests that monitor transplant recipients for injury or rejection, posted third-quarter net income of $19.3 million, but an $8.6 million income tax benefit did much of the work. Pre-tax income was $10.7 million and income from operations was $8.1 million, according to the 10-Q the company filed Thursday.
How the tax benefit arose
CareDx bought Naveris on July 1, 2026 and recorded about $10.2 million of net deferred tax liabilities on the deal. That let it release about $9.8 million of its valuation allowance. The release was booked as a discrete tax benefit in the quarter.
Because the release relates to pre-existing tax assets, the filing says it was recorded outside the acquisition accounting and did not affect goodwill. Net income a year earlier was $1.7 million.
The quarter also carried $3.7 million of Naveris acquisition costs, expensed as incurred.
Prior-period tests padded revenue
Revenue rose 39% to $139.4 million. Testing services revenue grew 65%, including $12.5 million from NavDx tests after the Naveris deal; volume growth excluding NavDx was 20.8%.
The gap between revenue and volume growth came mainly from $17.3 million recognized for tests performed in earlier periods, against $5.9 million a year earlier. A $2.6 million increase in refund reserves for payers partly offset it. The payer refund reserve stood at $16.4 million at September 30, against $3.5 million at December 31, 2025.
Naveris contributed about $12.5 million of revenue and a $6.4 million net loss in its first quarter inside CareDx. The company's earnings release raised 2026 revenue guidance to $520 million to $530 million.
Provisional Naveris numbers
The purchase price was $203.3 million, including contingent consideration with an acquisition-date fair value of $44.0 million. Goodwill of $85.7 million is preliminary and can be adjusted for up to a year after the close.
Former Naveris holders can earn up to $100.0 million more, tied to NavDx revenue for 2026 and 2027. CareDx says its NavDx revenue forecast drives the valuations of both the intangibles and the earnout, so shifts in it could force material changes to the liability or write-downs of goodwill or intangibles. It also says it has limited operating experience in specialty oncology.
NavDx coverage depends on a single Medicare coverage decision, which the filing warns could be revised or retired.
Dates ahead
CMS preliminarily set the 2027 AlloSure rate at $2,840, up from $2,753, with AlloMap unchanged at $3,240. Final rates are due in November 2026. Oral argument in Natera's appeal of the invalidation of its patents asserted against CareDx is scheduled for November 9, 2026.
CareDx held $250.5 million in cash and no debt at September 30, with $100.0 million still available under its April 2026 buyback program.
Sources
- 10-Q Filing — CareDx (CDNA) — SEC EDGAR
- 10-Q Filing — CareDx (CDNA), Q2 FY2026 filed 2026-07-30 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, cdna-20261029_earningsrele.htm) — CareDx, filed 2026-10-29 — SEC EDGAR
- CareDx (CDNA) After Kidney Week Data Is The Story Already Priced In — Yahoo Finance
- CareDx Non-GAAP EPS of $0.70 beats by $0.44, revenue of $139M beats by $17.04M (NASDAQ:CDNA) | Seeking Alpha — seekingalpha.com
- CareDx Inc. (NASD:CDNA) : Articles :: Law360 — law360.com
- CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus — Yahoo Finance
- Long-Read Full-Length cDNA Sequencing Global Market Report 2026 | Capitalize on 18.9% CAGR and Single-Cell Demand With PacBio, Oxford Nanopore, 10x Genomics and QIAGEN — Yahoo Finance